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Althbwgh antitiombotic therapy ig dearly beneficial in the 
treatment of acute myocardial infarc$un, there: is controversy 
regarding the optimal regimeri. Trials cozn&ted t;etween 1972 
and 1981, before the rcutine use of asp& and thror;&oIytic 
therapy, provided evident+ of benefit frc?m heparin. In l!l%Z, 
aspirin (162.5 mg daily) was demonstrated in the Shwnd 
rntemationaf Study of Infarct Survival jlSK$2) trial to reduce 
mbrtality, reinfarction and stroke (1). It is clear that thrombo- 
lytic therapy also confers a substantial mortality beneftt (2) that 
is ad&&to that from asptiti alone (I). The use of immediate 
:ititr~ven&s &pa&in’ a&e niyxhdial &far&n. is *de- 
sprea& the United &es, but datA ~itpporting this c&al 
practice are ccmroversial(3). The addition of delayed subcu- 
taneous heparin 50 aspirin pius thromWytic agents was inues- 
tigafed, iti the Second Gruppo Italiano’ ‘per lo Studio della 
SoprovGivenza ne!l’Infartci Miocardico (4) ‘&id’ and its lnter~ 
nationQ s&dy Group,,(S) (GISSI-2) and in the T&d Interna-, 
t&al Study of lnfarq Survival (ISIS-3) (@j *al. Until re&ntiy, 
randomized .tial d@a were S&K& regardiig the riski; and 
.benefits ,df time&ate intravenous heparin. lti 1993, the F&t 
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muiti~nter @n&e-btind st+ tif !,427 mea and worn&~ ifi the 
United Kingdo=, ,’ +i@s with ~.Ir81?:t~- or prbbable’. acC 
myoca;did itiarctior~ were ~,anhrtized’ du+g ,tLt: ;hospital 
per-i@ tu tkdve either,.ir- ,3L~~~-inous ~rcparin (lS,QQ&lJ ,bolus, 
theri 10,000 U every 6 h-for 36 !I) pin !@I dose phcnindione 
(an oral anticoagulant agem.” or no &parin plus, ‘low dose 
@~etindione (12). In the PWSX Municipal Hbsp+al Centgr 
-IX& 1,136 men~and women hacieents v~ rgndomized’within 
24 h tif admission to reuzive heparin (S,oGi)-,U intr~v&r!otis 
bob, fokwq.I by lO,NKl W subcutaneoukly every 8 h up to five 
dye@ plus phenindibne or to receive placebo heparin injed- 
tions @us placebo phenindione tablets (13). In the Veteran 
Admiuistratioa Co@erative TrjaI,’ 999 ‘male, patitnts were 
randomized within 72 h of symptoms ‘to Feceive either heparin 
(10,000 ?J &bcutaneously until the clotting time was pro- 
&-mged) plus w&win or placebo ,therapyfl4). 
,Although features of each of these trials were not suffi- 
ciently sim&r fo formally combine their findings in a quanti- 
.Wve m&a-ana@&+ the range of averall reduction in mortality 
r@e was ~XNII ,100/o to 30% .in patients givfn heparinmntaining 
regimens, with eveit larger benefits for, stroke,’ gurnionary 
emboli and tiwarction. The risk of bleeding complications iti. 
the heparin ‘ttyeatment iny was significantly increased in all 
‘t+s (by a factor of 2.3 to 3.9). but there were no fatal 
hemorr&@c events. Concomitant randomization to prolonged 
&al anticoagulaunf therapy makes it difficulr to attribute the 
bene&‘,or. risks solely to heparin. However, even if an 
apparent net b&fit wer& <:aused by beparin alone, +tr?pola- 
aioa~to current mauagemer,t of myocardial infarct& is limited 
b&use therapies that ar!: currentIy considered iifesaving- 
aSpi&, tbrombo!ytic a@na beta-adrencrgic blocking agents, 
&igk&@n-&mverting enz~e inhibitors, immediate pcrcuta- 
nems transluminal coronary angioplasty and emergeng coro- 
nw artery bypass surged--*ere ‘not yet widely utilized at the 
time ol’,these trials. 
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Aspirin ‘None’ or &pi& With’ Cqnmrd&tit 
there ws no diffeiefice in the incideqce of-cerrtral @e,&rL I 
A-- between the aspitii~ and plqxbo gr&q$There weie also *A’-e’ 
no, significant -differences betwe@ .chese groups in- bleeding, 
-rtiquiring transfusion (0.4% fdr both), ,although th& was’ a 
sm$l, significafit incr&si : of: 0.6% for minor bleeding’ am&g 
tlib$ all&ted to *spitin (1): i : : j 
I $i the United States although‘She +jority of Qatients may 
be -eligible for throriIboi:;il?, thqapy, only 40% of paticm in a 
multicenter mydcardiai rpfar&c ,regis:y .wcre Zreared (I$, 
atid .only 2Pc”, utilizzation WE ‘i~cn ;n a more recent broad 
WWF qf in-hospital patierrrs {it). It is clear that more 
widcsprqar; use; is possible ,zmd will tive ‘more. lives (17j, 
esfieciaZ;t in. patients with :$T- segment tiievations or bundie 
branch Irl~b on the electrocardiogram (ECG), ,age ~65 years 
and tiisc of :~csentation within I2 h (2) The decision whether 
to add thronrbolytic theraW to aspltin depends oil the a&&- 
pated balance of added benefits against risks. However, with 
regard to aspirin, given its very favorable benefit/risk ratio 
when given ITI a LI! antithrombotic dose (i.e., ~162.5 mg), 
virtu&lly ail patier& with acutq m~~cardial infarction should’be 
c&sidered for immediate tre,-Ement (18). N&zrtheleSs, aspirin 
remains underutilized in a=ute myocardial infarction. For 
exampie, only 72% of patienis were receiving daily aspirin after 
myocardial infar&on iri a- recent study of U.S. academic 
centem (IO), and only 4°C’ 6 of Medicare patients now receive, 
im,rcdiate aspirin (20). 
In patients treatr:d wika aspirin but not.receiving’thrombo- 
lytic therapy, there :.ave been no trials of adequate sampIe-size 
to test the h,pothesis that heparin therapy preventsdeath or 
reinfarction; Only st&roup data aFe. av@able fr6.M $evetii 
recerit ’ Iar& thromb&tic tri$& .For ex&p&; in- the Late 
Assessmeat of Thrombofytic Effiacy (LATE) triai (21j, pa- 
tients presetiting 6 to 24 h from symptom onset were: random- 
ized to receive either aspirin plus conventional-&se tissue- 
,type plasmiiogen &ctiva& (t-PA) dr, Gpiriri pi& t&PA, 
-~pl&c+o~ ‘Reparin ~21s not r&ii.red by,the aticiy protocol; btit 
,d&ing the course of the trial its‘use iras remmended in -& 
prots lbot arriendmeut; Ainong t& 2,860 patients rtidomized’in 
the -L&i Assessment of ‘i’;zrombdl@c .Efficacy (LATE) .I+, 
.tiho,‘diq not :&$ive thrombo&&, 1,849 ;receivrd adj&tive 
.hep;irin, alld l,Ol 1 did -not. At 35 days; 8.7% of those tr&ed, 
with hepariti:died cornpa+ ‘with 12.9% of those .not given 
hepark; a @Scmt differekg (p < 4UlOI). ‘,. : i i 
‘. Xn contrast, there *as no apparent benefit from’&-protoctil 
,‘I& of heparin in. fSIS-2. Amun~ the 4,295 @&i& randomized 
to receive aspirin but ‘noi thtimboiytic therapy, there was no 
j signifitini di#T&nce in tiorta!ity rate: at 35 d&s between 
patients v$o did and did not receive off-protocu1 beparin: 
..10.9% in the 1,024 patients assigned to receive intravenom 
TaMe.1. Pa&y Trials of b&venous !ieparin in Addition to at Least iS0 mg of. Aspirin in:Pat/ents 
.;’ 
With Acute ,Myocardial Infarction Treated With: Tiworhbolysis .., 
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% of & With Coronary Pat&y., 
‘. tv 
Tidal (ief. no.) : .T&tment 
‘Time Fiom Thmrnliolylic FC No ~ ., 
; ,+Wministration Ikparin Heparin Hcpwin : 
OSlRlS(25) ,SK +AsA; 60 min (n = :iZRf n ‘- 60’. 
‘IV heparin 90 min (n = ,IzX) R2 - 72’ 
or pIact& 24 b (n = 128) gJj .--’ 87 
txrcs-~~2bj ‘APSAC i ASA; .i da!.% (n = ?inj 
: 
x0 _- 34 
‘IV hcpatin 
of plaaho 




GUSTO-I (33) SK + ASA; 9U min (n =; 576) ho 54 - 
IV heparin 180 min (n = 2:s) 14 73 - 
or SC hcparin 4-7 days (n = 189) 84 72 - 
*p < 0.05. tp = 0.02. APSAC = ankoyI;ated jdasminogeri strepiokinase activator complex ASA = aspirin; 
DUCCS = Duke University Clinicat Cardioiqy Study;.ECSG = IZuwpcan Cooperative Study Group: GUSTO = GlnbaI 
Utilization of Str~ptokinaw and Tissue Plasminogcn Activator for Occluded Coronary Art&s; 1V = intravenous; 
OSiRtS x Optimization SIudii of Infarct Rcperhision hn$s:ig&d by ST MonitolingPts = ptients; ref. s rcferertcc: 
SC = subcutaneous: SK = strcptokkze; I-PA = tkue-type ptasminog.irn activator. 
heparin, 11.2% in the 1,8GO assigned to receive subcutaneous 
hepatin and 10.1% in the 1,471 who did not receive heparin 
(I), Further, amo+g the QXl patients ybo received neiiher 
aspirin nor thrombolysis in JSTS2, there was also no reduction 
in mortali~ rate associated with off-protocol heparln: !?.I% in 
the 1,023 assigned to reo:ive intravenous heparin, 13.5% in the 
1,800 assigned to receive subcutaneous beparin and 12.9% in 
thz 1,477 who did not receive heptin (1). Howetzr,. neither 
these data nor thw ftorn the LA? trial were ranciomized, 
and patient characteri:;tics probably differed substantially be- 
tween those who dkl and did not. receive heparin. ,Such 
subgroup analyses are +uI for foqnulating but not for testing 
hypotheses (22). .: :. : ‘, 
:. These ab@ently confli+ng dat! incr&& th&~‘diticulty .of 
determining whic.h pa$ent$ among thos? Mat&d with only , 
aspirin .buj not ‘thrombolysis, shouM bc considered for the 
&n.vmitant. administration ot hepar@. Therefore, -random- 
ized trials are necessaryto co~pa~‘asp$in &ne with *pitin, 
plus either heparitl ol;‘ ,wwer tintithrombotic ihcrapies. ifi: 
patietits with’,swp$ted acute myocardiai’infarction consihered~ . 
ineligible for thronrbolySi.9. + recently begun lar&scale trial is 
d&c@ t+ting Ibis hypethesis. TBis ,@ial. die Fir& Americ& 
Study of Infarct +tiival ‘(M&t ). $11 randomize, 1:2,000 
patients with acute. myocardial- itiarctiula not rtxeiviqg throm- 
bolfsis to remiv~ aspirin a!one, -$spi+n ptris’, intravenous,, hep- 
itin or ‘aspirin plus inttiveti@us i-iiirudin ‘$23). : .’ ‘.’ I ; i .; 
adding hepariti Conferred net benefit, net berm or no &ect, 
Data an this issue ar&available fron! sina!1 patency studies of 
intravenous heparin as weil as from’ large mortality trials of 
delayed subcutan.eous or immediate intravenous heparin: I’ 
In the United States, intravenous heparin-is widely used as 
a routine adjunct to thmmbolysis and aspirin on basis of the 
possibility of added bene#it from improved coronary arterial 
patency (24). Several angiographic trials have assessed the 
efcect on coronary pateficy of adding intravenous- heparin to 
thrombolysis and futl dose aspiriti (Table I). -0 of these 
small trials evaluated intravenous heparin compared witli no 
heparin in the present of streptokinase or’anisoyfated plas- 
minogen+eptase activator’complei .(APSAC ,[a&tre;ptase]) 
(25,26) .+d found .no si&ificaM &Beer&z in pat+$&jetweeti 
‘i the grtiups. Wjth regard to t-PA, a third study (27) showed a, __ _ ~. __~ 
>I@ small imy movement in patency, although this did not 
&rreiate with I;?pry:ed, +zymatic infm size or d~inisbed 
” incidence of reutirgnt is&r&Thus, fhere are little data that 
hqarin c&f&added pqtenq benefit in the presence df fill! 
dose, aspirin. Ncinethe!ess, the: tie&e! b&s pc&ed thai,imtie- 
di& ]iutravenoti hqiarin is a ne&&ry adj:mct to theraW 
with t-P&!, la&y on ‘the +$&of eqrliei results from ‘SUIT 
p&en& trials;, one thztt .coTpaied .iimrnbdi$e intravenous 
heparin is. no hepal-ir! inrthC:,absence of ‘aspirin,,(28) ,cFd 
another t@at ~rnptir$!,:~~t 38 ti, intravenous heparin with 
3G “I& d tipi& (29, a :dosethbt dots tiot achieve a din&al 
antit$rombotic cfFect for at least 2,days #ter a.dmi&tration 
: ”  : 
Heyip, Phs; &@-in -89, Acqjuac)Sve Y+esapy 
(30). : ,, ; : -’ .’ .’ : 
,. ., ” ’ 
TIC &yst large mortzili~ ,.@ial to stydy the ‘&ddition of 
.’ .-“tq Thmm,boly~is’ ‘, 
Aft& ItSB-2 &nch&vely demgnstrated the efficacy 6f aspi- 
@zpar;n to b&as@@ and th~ombolytic therapy was GESI-2 
(4,5), which directly compared the’risks and benefits of delayed 
rin pius thrombolytic tbgrapy, .it remained unct -ar ‘whether subcutaneous kpti with those &f no beparin’ among 2GJ391 
,TaMe Zi D&t F&m Lkct cOrnpa&& of. A@woi&ootic Regimens: GISSI-2, WS-3 and GUSTCITL 
_-- 
OISSt’i ad ISIS-3* ’ 
:.: (Asi pllig~y @xnbolytie agent) 
.Gf-F?lU-lj’ .: 
.>’ ..’ A - I c&G+ ph!s$K) : ,. 
&&& :. 1 
No i-kparin SCHeparin : SC Hqkin IV Iieparin 
(ty -r 31,rnO) (‘I = 31.017) (n:= 4,yi) : (n = losnj, ‘. 
: L&r&;. : : LO.2 : 10.0 7.2 7.4 
~eittfar&m -3.3 ,: 3.0 3.4 4.0 
Total !mlke ,‘I.Z’ I.1 1.3 1.4 
FrcffwnJl* strdii 0.4. > 9.5 0.5 n.5 
Majdr bInding 0.7 to 0.3 t-b.5 , 
!Major bkeding, p < 0.05 forsudeutaneow.(SC) versus no heparin; no signiftcant difFerencea for the other outcomes. .& 
’ tR@@&t.: 2p C: 0.0001 fclr sikxutane& VIRUS irkvenous (IV) Leparin; no si@fic&differencer for the ather’ 
.’ -’ otttwt5es. Out&my @xprked 3s %) are at 35 days for Gruppn ftaliarm per In Studio dell+ Soprrrwivenza nell’lnfano 
‘. Mio&dico (GISSIJ I4,S]. 30 days for Glabal Utilization of Streptokinase and ‘lbue Plasminogen Act&ator for 
&c.iutkd Catpnmy Amtics (GUSTO-1 [7]) and 35 days for Third Interrptialrl Study of Jafarct Survival (KlS-3 lb]). 
patients presenting within 5 h’ of symptoms of myocardial 
infarad. All patients were also rmdomized to receive either 
siqakinase or-t-PA. J-kg.min (l2,!JOO ‘U).was begun 12 h 
afgr in&i&on of. thrombolytic therapy and contim@ twice 
d!dy far 7 days or &tiI~hospital dischkge, and’it was recom- 
yrsded that aM patients receive 300 to 325 mg of oral as$tiif 
d&y starting at the time of randomization. The additiou of 
&da;.+ subcutaneous heI&r to furl dose aspirin piu: thrown- 
bolps had no aignifibt effect on 35day’(9.3% vs. 9&j or 
in-hospitaK(8>% VS. 8.9%) rnortatity rate. With respect o,side 
t$f&cts, the incidenec of bleeding requiring transt&ion C -MS 
d0aHed in thllqmrin gruu~ (Ix% vi. 0.5%, 2p < o.f.Mi): 
despite the delayed subc).rtaneous administration (4), which 
appears to have ,a variable and .onIy moderate effect on the 
.evated pllrtrial thromboplastin time,,(31]. 
The ISIS-3 t+ iimihtly compared the r&s and benefits of 
dekyed g.hgutanectus hepm-in with those of no heparin amon@ 
41,299 pa&n& with evolving myocardial ,infarctior, enrolled 
with& 24 h of symptom unsea (6). AI1 patients were aIsa 
rfmdl3m~ to rBoeive~ one of ‘three thr+lbo&ic &J&s: 
strept&uase, t-PA or.APSX Weparin &Z,500 U) was begun 
,4 h.af@r initiation of thrombolysis and continued flit 7 days or 
until hospital discharge, whichever &me firit, rnd ail p.;tients 
IctW5wd eiairy aspirin (I62 mg) foi SO days. ,*T?lere v’erc no 
significant cli&xeq~s in 35day mortaiity betmen’ the heparin 
pb aspirin group Veraus the asC.n alone group. There was 
t&y no ai&icant diifwmce in morWy during the scheduled 
llqlah tferatsaent~ period, a&hough there was a significant 
raun in this -aonpresp~& end $oint in @e ccimbiied 
data fmn I%§-3 and GISSI-2, (&p&n 6.8% vs no h&pa& 
73% 2p -=z 0.01). As in ~TSSI-2, ti+ addition’. of delayed 
%s&caltaneow heparin tO aspirhr iv&ii ass0ciatd with higher 
freqnetrcies of both major bIeediag requiring tr&sfusion and 
of d&&e or ‘probabIe cereb&l hemorrhage (6). Therefore,. 
taken mgsther, the GI§SI-2 and ISIS3 trials prqvide cmih- 
tent &ti an M2,oOO patfeats that the addition ef delayed’ 
ltuberrtauenlls hqarili to Pi regimen of aspirin and thrombaly5& 
fB%WidW’nO Sl@MCWt W5&i.~ iWdit)f b&i but ti 
ran& fn ‘821 0wem af m* bied~ng and d -1 per 1$Jx) 




Despite the excess of serious bleeding events in both 
GISSI-2 and ISIS-3, it has been argued that these ,data are 
inadequate to assess .the true benefits end risks of heparin 
admiuistered intr&enou.sIy inste.gd of s&cuta&o$y, early 
(within 4 h of administration of thromboiytic therapy) and ai 
infusion rates suilicient to eltiate the activated partial throm- 
boplastin time consisrently above I.5 times control ‘(32)., The 
GUSTO1 trial (7) directly addressed these i&ses by compar- 
ing delayed subcutaneous with immediate intravenous he@rin. 
In the $XEI’G-1 .@I (71, patients were randomized to two 
streptokinase ,egimens, one -u@ng ditayed subcutaneous hepi 
a& ‘(the same as in-ISIS-3) and the otbr using immediate 
‘~.,Irlttavenous heparin (Le., a 48-h in&n& starting with a 
Y UIO-U boius Eind 1,~U/h infusion, with subsequent dose 
& dinents by a prespecified nomogrim). The two other trial +ft 
,at& i:‘~ GUSTO-I us!:d new “accelerated” i-PA re+gimcns pIus 
immkdiste intravenous heparin, but thu risk/benefit ratio could 
no*--be compared directly because there was no trial: arm of 
ac&erated t-PA plus delayed SubcutaneouS hepariu. .As in 
GISSI-2’ and ISIS:$ $lI patients received at least Mb mg of 
aspirin, and- those ~ndor+d to the &eptokin& ‘&ms 
received the same mnventionaf d= and method of adminis- 
,ttation of streptoldnti used in the ISIS and GISSI trials. 
bstll&.of GUSTO-1 (331, 
between patients random- 
inmvenous hep;;lrin and 
ase pi= subcutaneous 
arty& the other time 
phis subcut+ous hejiarin (35), bui the-al+ence of a compa- 
rabte -a$., 0%. a~~~ierkd t-P!4 FIIJS SubCUtaneous hcp& 
m&es If,, impcissible tn ‘attri&te &fferences in patency ~ to, 
intmveuous hqp&n. .Ftiher, in. this bpen+&el d@b, tkie 
was si&ficrnt crosscjver to intrayp~%~s heparin, among those 
ini&ally rz$&mite$ to receive subcut&oti heparin; an c&t 
&at is ,likely ; to dilute the magnitude and: significance of 
,b&eficial,or adverse effects fFdm i&venous. heparin. Thus; in 
GuS+%i for parients treated with aspirin plus cOtivcntior&i 
don *:treptokinase, there is no apparent added clinical benefit 
but some lx&ble advcrst effects from intravenous beparin 
.(Tahle 2) (7). 
‘: No mortality trial has made the direct dotn&rison between 
‘he of intravenous heparin and use of either subcutaneous-or 
no heparin in patients treated with either, t-PA or APSAC (3). 
H~kvet, the LATE trial provides n&randomized stibgroup 
data for adjunctive heparin with. aspirin plus t-PA. Among 
LATE patients randomized to t-PA, 1,814 patients r&ved 
elective heparin and .1,007 patients did not, and there was a 
statistically sign&ant reduction ‘in 35-d& mortality rate asso- 
ciated with hepatin use (7.6% vs. 10.4%; respectively) (21). 
Howe&, there was a trend toward’mor&&y benefit of t-PA 
treatment campared with no. thrombolytic agent, .whether or 
not patients received elect& h&par& and the relative mortal- 
ity reduction attributable to t-PA was act&y greater for those 
who did not receive heparin ‘(24.46) than for those .who did 
receive hepadn (14%). Such subgroup data must be inter- 
pret&l witIt caution (22), because it’ iS Iikely that other con- 
founding factors contributed to the decision to administer 
boparin elr&ively. 
Safety questions have rerxntly been. raised &out high doses 
of intravenou$ heparin as used in the’ Second Global Use of 
Strategies to-Open Qceluded CiPronary Arteries (GUSTO-2a) 
(34) and- the Ninth Thrombolysis and Thrombin Inhibition in 
Myocardial Infarction (TIMI-9a) (35) trials. In addition to the 
Tliird r-Hrudin for Irriprnvement of ,?$rombolysis ,[MIT~3) 
(36) i+l, these ihi ijie first large clin&l trials investigating the 
use of r-hi&din,, a recombinant direct thrombin inhibitor, 
hypothe&ed to field a benefit/risk ratio superior to that for 
heparin, In GUSTO-2a and TIMI&+, patients receiving 
thrombolytie therapy plus aspirin we- randomized to receive 
-either immediate high dase intravenuus.heparin or-intravetious 
i-hitidin; In both GUSTO-23 and TlMli9ai the ‘dose ‘.of 
heparin was a 5,000-U bolusaad l,fKtO- to 1,3tKW/h infusion, 
and that of r-hirudin {Ciba-Geij& k a O,6-mg/lcg botJl weight 
boluS &id O.&m&kg ;per h infusio& ,me trials wzre termi- 
nated early because of cxbessive rates bf intracranial hemor- 
rhage in patients randomized .to receive both hep@rIn B+W ” 
r-hirudin, land each irial has been restart,-:< ir ??-.;“,g’*i’iQ’ !‘;- 
I lower do&i of both agents. (34.35):. In )ii“.~.i. h!J p,itkr.(s 
reeeivcd acc+&tcd t-PA plus aspirin :- ,e? were r&io~~x+d to 
receive a. I- aggressive weight-adjusr+l hcp .W dlxe (70 Ufig 
&~d lWJ/hg per h~initial,infu&n) or to’t&ir:~L~, !Rehringf 
werke) (O.&@kg bolu.; and ~O.l5-m#kg per h irS&m), In 
MIT-3, despite small numbers, there was an erioess.of infracr5 
nW bleeding am&g the hirudin’group’comp&d with that in 
:  
-the hep& greup (5.G. ft, p .= @iIS). N&ethciess, the totali& 
of evide&e, wh:& in++ ‘GUS-ID+ and Tlhll-!?a, led -to’ 
the’ decision to;,ferminrle HIT-j. (36)..Thus;both a&$es&ve 
inti;avenous hepadn and t-hit&din may have narper thera- 
p&&toxic ratios than previotisly hypothes&l; These data 
add fi.trther~‘su~part .to, the need for’ direct ~mparisons of 
asp/am ala&. aspinn plus intrsvLn.npt+ heparin andaspirin plus 
intravenous hirudin at doses of both’hcparip and hi&din more 
likely to confer net h~cncfit, as”in the ASIS-I trial of pati&ts 
who do not receive thrombolytic therapy (23). 
Net ke&fits md Risk&of heparin tided to 
Aspiria in Acute Mpcardi~l Irafarctiosr 
Although the quality and strength of datavary for different 
combinations of antitkrombotic and throcnb@tlc regimens, 
randomized trials alIow clinicians to weigh adequately the 
benefits and risks of adding currently recommended anti- 
thrombotic regimens to aspirin’or’ to aspirin plus,thrombolysis 
(Table 3). In general terms, for every 1,000 patients admitted 
to the hospital within ‘6 h of onset of &pected acute myocar- 
dial infarction who do not receive Ehrombolytic therapy, -132 
die tijthin 35 days (1). The addition of full do?: aspirin 
prevents 23 of, these early deaths with no increased, risk of, 
nonfatal ‘eerehral hemorrhage and the avoidanre of hvo dis- 
abling strokes. The us of tlrromtioiytic the’rapy (streptoldnase) 
avoids an additional 30 premature deaths, but with a &corn- 
itant increase of two to three nonfatal cerebral bleeding events 
but a decrease of three to four disabling ischemic strokes, !and 
thus, one I& total stroke. The reduction in mortaltty resulting 
from the combination of aspirin and thrombolysis ii additive, 
resultitig in s savings of -52 deaths per l,OQO patients treated, 
within b h (1). Tnus, al1 patients should he considered c+ndi- 
dates for aspirin, and thrombolytic therapy should be given to’ 
all patients in whom the fiqenefit ratiu.ia. favorable (2): 
; .F& p&u6 who receive both aspirin and thrombolytic 
therapy, GIS!?&2 and Isis-3 indicate ti significant mortali& 
benefit from delayed subcutatieous heparin. In GUSTO-l. 
.paEienEs given aspiriti and streptoldnase, there is rtb a&itional 
‘mortality ,benefiE frern, intravenous heprnin administered .by a. 
rigorous dose-adjustm.ent uomogram. ,,at present; no large-, 
se&e mortality .trial has studied patienti treated with full dose 
aspiriu plus either +&PA or APSAC- randomtid. t6 receive: 
intratiti~us’hepsri~r v~rsus.zubc+ineuus or nd- heptin. I!*? 
ever, ‘.a&‘.ind@aied e;:rlier; patency data f-y &?‘L4C &Lx+ 
‘supp&r the uee i 1 adjunctive ,int&Y?tr::’ rl a~-~.&& Aereas 
patcicy d&a for t-PA sU@est at most, + &ITXIZ! :F’& for 
intiavenblis,heparin.~n~ fuil k&e,asppirtn brs txzcn given. The 
coritinued uncerr+ty ;.b~~~it:magnitti~e,of benefit and increas- 
‘hrg concerns’ repding risk &se qucscbns about intravenous 
; .hepariu&htin added: to any available #i~rxnhnl\rtic agent plus 
adeqtitez dose aspirin. This is a cyxern that &tay apply 
particuta; ly to patieafs at greatest Ask of intrscerebral bleed- 
ing, such as those who are elderly or hypertensive (2) as weir as 
thhe who are treated with adjunctive t-PA f4-7)a 1. 




Ii%pwkd Cl&al E&cl? 








Possibly low to 
lWO&mte 
PawMy low tu 
fflcdcram 
luw to moderalc 




‘Gmding system: A = rasdo.nized tri:! data in iarcc wunbers of patients, B := randomtied trial data in small 
wmben of p!ients or meta-analytic dab ,of mulfiplc sma:i I andomized trials; C’ - subgroup or other nonbndomizcd 
&fa from large prospective randomized ttiis. tComparisnns of rxpcctcd clinical bcnctils or risksof adjunaivc regimens 
containing-~rbcrtaneous or intravenous htpatin arc described as J ctimparison wiih the regimen containing no heparin. 
ea@jal infaretio&, We believe thar avaiIabIe’dtita ‘from randark 
iad mortality and patency tria!c 3re w.wntIy iwsdequate tc 
jud@,tihether ruu&e use cf imni&lia:* ;*,-,avenous heparin in 
.kdd&m to full dose aspirin confers net benefit, net harm or no 
e&et. Par psifieokwho do not Tive thrombolytic therapy’,-: 
ASS-1 will pycwide direct evidenti tith ‘k&ard to benefits and 
i’isb of asph$ti alone, aspirin pIus intravenous heparin and 
mpirin ph@ iqtra~eaons hirubin. The ex&& data support the 
neexl for otBg0Gkg ,arld future ‘trials of prtising alternative 
thrombirr i&ii~to~ such & hinidin, himlog and tow molecular 
weight hepark. R+domi.zedtri& of su+ently large Ample 
&e are requked to provide the most reliable infwmation for 
,bot) izhiitians ed policy makers regarding the kxe of these 
ageMs in p&ents treated tiih’aspiriq plus thro$4yti& theri 
spy as w&l IS those who T&Y~ ‘aspi@ but who are not 
cmdidates for thrkboiysis; ’ ” 
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